HighTower Advisors
GNMX

HighTower Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

HighTower Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-16,600
Closed -$129K – 1635
2013
Q3 		$129K Sell
16,600
-1,000
-6% -$4.64K ﹤0.01% 1202
2013
Q2 		$67K Buy
+17,600
New +$72.1K ﹤0.01% 1204

Other funds holding GNMX

Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HighTower Advisors's GNMX Position: Q4 2013 in Review

HighTower Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2013, closing a stake of 16,600 shares — an estimated $129K sold.

HighTower Advisors first reported a position in GNMX in Q2 2013 and held it in 2 quarters. The position peaked at $129K in Q3 2013. 26 funds tracked by Wall St. Rank hold GNMX as of Q4 2013.

  • HighTower Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q4 2013 after selling out during the quarter.
  • HighTower Advisors sold 16,600 Aevi Genomic Medicine Inc shares in Q4 2013, an estimated $129K.
  • HighTower Advisors first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 2 quarters.
  • HighTower Advisors's Aevi Genomic Medicine Inc position peaked at $129K in Q3 2013.
  • 26 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2013.

Based on HighTower Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.